Status: Recruiting
Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \[PF\], fixed-dose combination \[FDC\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Participants needed: 60
Trial details
Phase: Phase 2, Phase 3Age: 12+Biological sex: AllType: InterventionalSponsor: Qlaris Bio, Inc.Updated: Apr 3, 2026Locations: 1
Eligibility criteria
BCVA 1.0 logMAR or better in each eye (equivalent to 20/200) [+2]
History of active ocular disease other than mild to moderate OAG/OHT [+8]